AMN Healthcare Services

AMN · NYSE

$41.62+$1.12 (+2.77%)TodayMarket closed ·
Prev close $40.50

AMN analyst rating

BuyConsensus of 5 analysts over the last 12 months. 60% rate it a buy.
  • Strong buy0
  • Buy3
  • Hold2
  • Underperform0
  • Sell0

12-month price target · 8 analysts

Average $36.87 (−11.4% downside)

Low
$28.28
Now
$41.62
High
$42.00

Upgrades and downgrades

The latest rating actions, newest first

AMN analyst upgrades, downgrades and rating actions
FirmDateActionRating
BMO CapitalOct 9, 2026MaintainsOutperform
BMO CapitalSep 11, 2026MaintainsOutperform
CitizensAug 14, 2026MaintainsMarket Outperform
UBSAug 7, 2026MaintainsNeutral
Truist SecuritiesJul 22, 2026MaintainsBuy
CitizensJun 23, 2026MaintainsMarket Outperform
UBSMay 13, 2026MaintainsNeutral
BMO CapitalMay 11, 2026MaintainsOutperform
BairdMay 11, 2026MaintainsNeutral
Truist SecuritiesMay 8, 2026MaintainsBuy

The case for and against

Updated Oct 15, 2026

Bull case

AMN Healthcare Services is positioned favorably because its core Nurse and Allied segment is showing stabilization, with return to volume growth for the first time since 2022, improving bill rates, and an international nursing recovery that could support operating leverage. Q1 results materially exceeded expectations, with revenue up 100% year over year to $1.378 billion, adj. EBITDA of $166 million versus $123 million consensus, and margins expanding 280 bps to 12.1%, while labor disruption revenue of $722 million and Q1 cash flow of $555 million underscore strong earnings power. The outlook is further supported by manageable leverage at 1.6x, a targeted 2.0x or less across the balance of 2026, and potential normalization toward mid-single-digit revenue growth and double-digit EBITDA growth as all business lines trend back toward growth by the back half of 2027.

Bear case

AMN Healthcare Services is facing weakening fundamental demand as management expects Q2 segment revenue to be flat to down 2% Y/Y, implying an 8% to 10% sequential decline excluding labor disruption revenue, while organic segment revenue turned from 9% growth in 2024 to a 4% decline in 2025 and is expected to fall another 4% in 2026. Core profitability is also deteriorating, with Physician and Leadership revenue down 6% to $164M, locum days down 9% Y/Y, and segment gross margin compressing 120 bps Y/Y to 26.1%, alongside VMS revenue suffering a 35% CAGR decline from 2022 to 2025 amid secular pressure on temporary labor. The company also faces concentration risk because Kaiser Permanente generated 22% of consolidated revenue and 32% of Nurse and Allied revenue, while nearly $1B of debt becomes more burdensome as revenue declines and profitability assumptions weaken.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.